Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Hoffmann-La Roche
M.D. Anderson Cancer Center
Ipsen
Merck Sharp & Dohme LLC
Eisai Inc.
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
University of California, Davis
Emory University
University of Texas Southwestern Medical Center
Bristol-Myers Squibb
University of Washington
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Medtronic - MITG
University of California, San Francisco
Milton S. Hershey Medical Center
ImmuneSensor Therapeutics Inc.
SWOG Cancer Research Network
Exelixis
Incyte Corporation
Incyte Corporation
Incyte Corporation
Pfizer
Incyte Corporation
Stanford University
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Bristol-Myers Squibb
NRG Oncology
Mural Oncology, Inc
University of California, Davis
Thomas Jefferson University
Merck Sharp & Dohme LLC
Kymab Limited
Shattuck Labs, Inc.
Eisai Inc.
Novartis
Novartis
Washington University School of Medicine
University of Colorado, Denver
Incyte Corporation